OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel

ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel.

Dr. Chen brings nearly two decades of legal, intellectual property, corporate, and strategic experience across biotechnology, global pharmaceutical companies, private practice, and scientific research. Prior to joining OncoC4, Dr. Chen served as General Counsel of HiFiBiO Therapeutics and ENSEM Therapeutics, where he advised on corporate governance, intellectual property, financing, business development, regulatory compliance, and strategic transactions. He also held legal and intellectual property leadership roles at DSM.

Dr. Chen began his career as a scientist at Vertex Pharmaceuticals before transitioning to law, giving him a distinctive ability to connect scientific innovation with legal and business strategy. He practiced law at Jones Day, advising life sciences companies on patent and intellectual property matters. He holds a PhD in biology and a JD degree, and is a U.S.-licensed attorney and registered U.S. patent attorney.

"Steve's combination of legal judgment, scientific training, and extensive biotechnology industry experience makes him an excellent addition to our leadership team," said Yang Liu, PhD, Founder, Chairman, Chief Executive Officer, and Chief Scientific Officer of OncoC4. "As OncoC4 advances multiple clinical programs, expands its global operations, and collaborates with strategic partners, Steve will play an important role in supporting our corporate governance, intellectual property strategy, business development, compliance, and other legal matters."

"OncoC4 has built an innovative pipeline grounded in deep scientific insight and has reached an important stage in its development," said Dr. Chen. "I am honored to join the company. AI-081 is rapidly advancing in global clinical development as a differentiated PD-1/VEGF bispecific antibody, and ONC-841 is evaluated for its clinical potential in both oncology and neurodegenerative diseases. I look forward to working with the leadership team to protect and expand OncoC4's innovations, support the execution of its strategic priorities, and help bring meaningful new therapies to patients."

About OncoC4

Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologics for the treatment of cancer and immunological diseases. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well-validated targets across oncology and immunological diseases. Among them, AI-081 (cesalatamig) is a wholly owned and highly differentiated bispecific antibody targeting PD-1 and VEGF. Cesalatamig is undergoing rapid global clinical development in multiple oncology indications. ONC-841 is a first-in-class anti-SIGLEC-10 antibody currently in a Phase 2 trial for oncology indications and a Phase 1 trial for neurodegenerative diseases. OncoC4 has a strategic collaboration with BioNTech to co-develop gotistobart (BNT316/ONC-392), a tumor microenvironment-selective Treg depletion candidate targeting CTLA-4, in multiple solid tumor indications, including an ongoing pivotal clinical trial in squamous non-small cell lung cancer.

For more information, please visit www.oncoc4.com

Contacts

Media Relations
[email protected]

Investor Relations
[email protected]

SOURCE OncoC4